Pharmaceutical Product Development, Inc.

Pharmaceutical Product Development, Inc.

Pharmaceutical Product Development, Inc.

Overview
Date Founded

1985

Headquarters

929 North Front Street, Wilmington, NC, 28401, USA

Type of Company

Public

Employees (Worldwide)

26K

Industries

Other Business & Consulting Services
Pharmaceuticals

Company Description

PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. It operates through the Clinical Development Services and Laboratory Services segments. The Clinical Development Services segment focuses in early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment comprises of bioanalytical, vaccine sciences, GMP, central lab and biomarker testing. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.

Contact Data
Trying to get in touch with decision makers at Pharmaceutical Product Development, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman & Chief Executive Officer

Executive Vice President & Chief Financial Officer

Chief Operating Officer

Executive Vice President, General Counsel & Secretary

Senior Vice President & Chief Technology Officer

Chief Commercial Officer & Executive Vice President, Peri-& Post-Approval Services

Executive Vice President & Chief Human Resource Officer

Chief Accounting Officer

Chief Medical Officer & Executive Vice President

Senior Vice President & General Manager, Accelerated Enrollment Solutions

Board of Directors

Chairman & Chief Executive Officer at Pharmaceutical Product Development, Inc.

Global Chair at Gerson Lehrman Group, Inc.

Former Chief Financial Officer at Ally Commercial Finance LLC

Partner at Hellman & Friedman LLC

Partner at Hellman & Friedman LLC

Partner at Hellman & Friedman LLC

Managing Director at The Carlyle Group LP (Global Private Equity)

Chairman of the Board, Chief Executive Officer, Co-Founder at GNS Healthcare, Inc.

Managing Director at The Carlyle Group LP (Corporate Private Equity)

Paths to Pharmaceutical Product Development, Inc.
Potential Connections via
Relationship Science
You
Pharmaceutical Product Development, Inc.
Owners & Shareholders
Details Hidden

FPR seeks to invest in companies that offer an opportunity for an attractive return with low risk of loss of invested capital. They focus on companies which the most important factors of success are largely measurable and then concentrate on analyzing those factors. The firm has a belief that their long-term investment horizon will allow them to invest at prices that will allow room for added growth potential with reduced risk of loss. FPR will primarily purchase securities of companies that FPR believes to be excellent companies.

Details Hidden

D1 Capital Partners employs a global equity long-short strategy that also seeks to opportunistically pursue private investment opportunities for their clients, with flexibility to invest in opportunities that are perceived to offer the highest risk-adjusted returns. The firm focuses their research primarily on the technology, media and telecom (TMT), industrials, healthcare, consumer, real estate and financial services sectors. Geographically, their investments primarily will be in North America, Western Europe, Japan and China. There are no sectors or geographic limitations on their investments, however, and D1 Capital Partners may invest in other sectors and geographic areas that they find attractive over time. Their clients’ public investments long portfolio generally consists of securities of mid- and large-cap issuers that they believe meet certain criteria.

Details Hidden

Sectoral Asset Management specializes in managing global portfolios that invest in the healthcare sector. The firm employs a bottom-up investment approach that can be categorized as growth at a reasonable price (GARP). Investments are selected using a focused stock selection process based on primary research of company fundamentals and close contacts with company management to assess their scientific, business, financial and ESG aspects. Specific areas of interest include: Pharmaceuticals, Biotechs, Life Science Tools and Services, Medtechs and Healthcare Providers and Services, Healthcare Equipment and Supplies, and Healthcare Technology. Covered companies are blue-chips, main index constituents and companies with innovative programs identified through research and industry contacts, including recent IPOs. The investment process encompasses stock selection, portfolio construction and risk management.

Recent Transactions
Details Hidden

Thermo Fisher Scientific, Inc. purchases Pharmaceutical Product Development, Inc.

Details Hidden

Pharmaceutical Product Development, Inc. issued USD Common Stock

Details Hidden

Pharmaceutical Product Development, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onPharmaceutical Product Development, Inc. issued USD Common Stock

Legal Advisor

Advised onPharmaceutical Product Development, Inc. issued USD Common Stock

Underwriter

Advised onPharmaceutical Product Development, Inc. issued USD Common Stock

Attorney

Advised onPharmaceutical Product Development, Inc. issued USD Common Stock

Attorney

Advised onPharmaceutical Product Development, Inc. issued USD Common Stock

Counsel

Advised onPharmaceutical Product Development, Inc. issued USD Common Stock

Clients

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

The Government of the United States of America is the federal government of the republic of fifty states that constitute the United States, as well as one capital district, and several other territories. The federal government is composed of three distinct branches: legislative, executive and judicial, whose powers are vested by the U.S. Constitution in the Congress, the President, and the federal courts, including the Supreme Court, respectively.

Polaris Group engages in the research and development of biotechnology drugs. Its business activities include exploration and confirmation of new drug targets, design and improvement of large and small molecule new drugs, planning and execution of clinical trials, and manufacture and quality control of pharmaceutical drugs. It offers cancer treatment drugs, and contract development and manufacturing organization services for biopharmaceutical industries. The company was founded on February 9, 2006 and is headquartered in Taipei, Taiwan.

Key Stats and Financials As of 2020
Market Capitalization
$16.2B
Total Enterprise Value
$15.6B
Earnings Per Share
$0.35
Revenue
$4.68B
EBITDAMargin
17.78%
Net Profit
$120M
Total Equity
$-712M
Total Debt
$4.45B
EBITDA
$832M
Three Year Compounded Annual Growth Rate Of Revenue
16%
TEVNet Income
129.69x
Debt TEV
0.29x
Enterprise Value / Sales
3.33x
Enterprise Value EBITDAOperating
18.49x
Non-Profit Donations & Grants
$1,000 - $4,999
2014
$1,000 - $4,999
2013
$500 - $999
2012
Investments
Details Hidden

Medable, Inc. engages in the development of decentralized trial platform. It offers enrollment and screening, patient engagement, and remote patient and site monitoring solutions. The company was founded by Michelle Longmire, Timothy B. Smith, Perry Robinson, Fernando Waigandt, and James Sasson in 2015 and is headquartered in Palo Alto, CA.

Investors
Details Hidden

President at New York Venture Capital Association

Suppliers
Quanterix Corp. Biotechnology | Lexington, MA

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Evercore, Inc. Investment Banking & Brokerage | New York, NY

Evercore, Inc. operates as an independent investment banking advisory company. It operates through the Investment Banking and Investment Management business segments. The Investment Banking segment includes the global advisory business of the company through, which the firm deliver strategic corporate advisory, capital markets advisory, and institutional equities services. The Investment Management segment is comprised of wealth management and trust services through Evercore Wealth Management L.L.C. and investment management in Mexico through Evercore Casa de Bolsa, S.A. de C.V., as well as private equity through investments in entities that manage private equity funds. The company was founded by Roger C. Altman in 1995 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Pharmaceutical Product Development, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Pharmaceutical Product Development, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Pharmaceutical Product Development, Inc..